The stock of Edwards Lifesciences Corp (NYSE:EW) last traded at $76.88, up 0.17% from the previous session.
EW stock price is now 6.88% away from the 50-day moving average and 9.50% away from the 200-day moving average. The market capitalization of the company currently stands at $45.10B.
With the price target maintained at $80, Piper Sandler recently Upgraded its rating from Neutral to Overweight for Edwards Lifesciences Corp (NYSE: EW). On January 30, 2025, Stifel Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock increasing its target price from $75 to quote $90, while ‘Wolfe Research’ rates the stock as ‘Underperform’
In other news, Lippis Daniel J., CVP, JAPAC sold 330 shares of the company’s stock on May 09 ’25. The stock was sold for $24,560 at an average price of $74.42. Upon completion of the transaction, the CVP, JAPAC now directly owns 26,616 shares in the company, valued at $2.05 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 07 ’25, GM & SVP, Surgical Markowitz Wayne sold 268 shares of the business’s stock. A total of $20,121 was realized by selling the stock at an average price of $75.08. This leaves the insider owning 9,299 shares of the company worth $0.71 million. A total of 2.75% of the company’s stock is owned by insiders.
During the past 12 months, Edwards Lifesciences Corp has had a low of $58.93 and a high of $95.25. As of last week, the company has a debt-to-equity ratio of 0.07, a current ratio of 4.45, and a quick ratio of 3.66.
The net profit margin was 16.03% and return on equity was 16.73% for EW. The company reported revenue of $1.41 billion for the quarter, compared to $1.33 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 6.23 percent.
